Novo Nordisk to buy Dicerna Pharmaceuticals for $3.3 billion
Novo Nordisk is buying an RNA interference company for $3.3 billion, a research bet that does not change current GLP-1 prescriptions or supply.
Novo Nordisk agreed on Nov. 18, 2021, to buy Dicerna Pharmaceuticals for $3.3 billion, or $38.25 a share, in the Danish drugmaker's largest acquisition to that point [1]. Dicerna is a specialist in RNA interference, a branch of drug research separate from the GLP-1 medicines Novo Nordisk sells for diabetes and obesity [1].
Novo Nordisk A/S is a Danish multinational pharmaceutical company based in Bagsværd, Denmark, created in 1989 through the merger of two Danish companies that date back to the 1920s [1]. It employs more than 48,000 people and markets products in 168 countries [1]. Its product list includes Ozempic, Wegovy, Victoza, Saxenda, Levemir, Tresiba, NovoRapid and Fiasp, and the company's business centers on diabetes and obesity medications and devices [1]. The company reported net sales of US$42.121 billion in 2024 [1].
The $3.3 billion price worked out to $38.25 a share [1]. It came at a time when Novo Nordisk's market value had grown past the size of Denmark's domestic economy, making it the highest-valued company in Europe [1]. Novo Holdings A/S, which is wholly owned by the Novo Nordisk Foundation, holds about 28.1% of Novo Nordisk's shares and 77.1% of its voting shares [1].
Which diseases Dicerna's research targets, how its programs would fit into Novo Nordisk's pipeline, and whether any of the work relates to obesity or diabetes have not been disclosed. Detailed terms beyond the price per share also have not been reported.
Why it matters for patients
Novo Nordisk is a major maker of GLP-1 medicines, including Ozempic and Wegovy [1]. A purchase of this size shows where the company is putting research money, and its size means those choices can influence which kinds of treatments get developed [1].
The deal itself is a corporate transaction, not a change to medicines already on the market. No changes to prescribing, insurance coverage, pharmacy supply or pricing of Ozempic, Wegovy or any other Novo Nordisk product were announced as part of the acquisition [1].
Whether RNA interference research leads to new treatments for diabetes, obesity or other conditions is not yet known. No target list or development timeline tied to the acquisition has been reported, and nothing in the announcement indicates when, or whether, any resulting medicine would reach patients [1].
For people in clinical trials run by either company, or for patients watching for new options, the practical effect right now is limited to what the companies announce next. Novo Nordisk operates in 168 countries, so any change in research priorities could eventually show up across a wide market [1].
What happens next
The acquisition was announced on Nov. 18, 2021, at $38.25 a share [1]. A closing date, the approvals the deal requires, and how Dicerna's staff and research programs would be combined with Novo Nordisk's have not been reported [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.